key: cord-0962380-w0zejjyc
authors: Hoornaert, E.; Dachy, F.; Hansenne, A.; Bailly, S.; van Maanen, A.; Gruson, D.; Vekemans, M-C.
title: COVID-19: impact of vaccination in myeloma patients
date: 2022-04-11
journal: Ann Hematol
DOI: 10.1007/s00277-022-04799-7
sha: b951f9e7923eb094cf68715f2744c2e56cef83b1
doc_id: 962380
cord_uid: w0zejjyc

nan

The worldwide COVID-19 pandemic represents an unprecedented crisis that affects the entire medical community and appears to be a devastating infection in patients with hematological disorders, including myeloma (MM) [1] [2] [3] . Vaccination is therefore crucial in this population [4] . Seroconversion after COVID-19 has been shown to be lower in MM patients compared to the general population. The same is expected after vaccination, as different studies have already reported a lower antibody response after anti-SARS-CoV-2 vaccination in this group [5] [6] [7] [8] .

We investigated the impact of anti-SARS-CoV-2 vaccination in patients with MM or related disorders, excluding MGUS. Immunization was assessed after two shots of either a mRNA (Pfizer®/Moderna®) or a viral vector (Astra Zen-eca®) vaccine, using the Elecsys® immunoassay performed on cobas®8000 (Roche Diagnostics®) that measures anti-SARS-CoV-2 antibodies including IgG.

From March 2020 to September 2021, we determined the serological status at day 30 (median 36, range 1-148), of the first 164 patients with plasma cell dyscrasias that completed vaccination. Among them, 114 were affected by MM, 26 by asymptomatic MM, 8 by MGRS, 16 by AL amyloidosis.

The characteristics of our cohort were as followed: median age of 69 (range 35-89), median IgG level of 700 mg/dL (range 80-1840), median CD4/CD8 levels of 530/μL (range 58-1668), and 398/μL (range 33-4556), respectively (Fig. 1) .

One hundred fifty patients (92%) developed regular antibodies confirmed by the presence of the receptor-binding domain of the spike protein (RBD) antibodies, while 23 (14%) presented nucleocapsid protein (N) antibodies, suggesting a previous contact with the virus. Among these, 12 had a history of a positive RT-PCR nasopharyngeal swab and 11 were fortuitously found to be positive in the absence of any clinical manifestation (Fig. 1) .

Thirteen patients failed to develop any immunization; all had received immunosuppressive therapies (renal transplantation in 1, long-term corticosteroids in 2, cyclophosphamide in 4, anti-CD20 monoclonal antibodies in 4, both in 2) or multiple lines of therapies in 1. We failed to identify any link with immunoparesis or CD4/CD8 levels. As well, there was no correlation between RBD antibody and CD4 levels. All patients tested after the third dose develop immunization except those exposed to anti-CD20 therapies in the previous 12 months. Only one patient underwent an interferongamma-release assay testing that was negative.

Nowadays, with an 8-month median follow up after vaccination, if only 5 patients experienced a mild form of COVID-19 during the Delta-variant wave, more patients (n = 12) are tested positive with the emergence of the omicron variant, but there were no significant clinical manifestations, hospitalizations, or deaths.

In conclusion, SARS-CoV-2 vaccination provided an adequate coverage in our MM population during the delta wave since only five patients developed a mild infection after vaccination. Seroconversion was however clearly affected by the anti-MM treatment. With the appearance of the omicron variant, we observed an upsurge of cases, even of benign evolution, which questions this protection. Whether nonresponding patients will eventually develop T cell protection against COVID-19 remains also to be answered, as well as the positivity cutoff that measures neutralizing antibodies, the optimal vaccination schedule, particularly in the context of immunodeficiency, and diverse anti-MM therapies.

Impact of COVID-19 on myeloma patients

Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy

COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Response to first vaccination against SARS-CoV-2 patients with multiple myeloma

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment